Niagen Bioscience, Inc. (NAGE): A Bull Case Theory

We came across a bullish thesis on Niagen Bioscience, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on NAGE. Niagen Bioscience, Inc.'s share was trading at $65.99 as of January 29th. NAGE’s trailing and forward P/E were 24.96 and 19.96 respectively according to Yahoo Finance.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. NAGE formerly ChromaDex, represents the purest intellectual-property play on NAD⁺ biology—the cellular coenzyme essential for energy metabolism, repair, and healthy aging. Its patented compound, nicotinamide riboside (NR), marketed as Niagen®, is the only FDA-recognized NAD⁺ precursor with GRAS status and proven human safety, providing a formidable regulatory moat competitors cannot easily replicate. This foundation allows Niagen to operate across both nutraceutical and pharmaceutical channels, selling a profitable, clinically backed product rather than a speculative longevity concept.

The company’s patents on NR composition, production, and absorption have been successfully defended against challengers, while over 100 peer-reviewed studies and 25+ clinical trials cement its scientific credibility. Competitors like NMN and NRH lack approval and safety validation, giving Niagen category leadership among physicians, researchers, and global consumer brands. Its dual-channel strategy—ingredient supply to partners like Nestlé and Thorne combined with its direct-to-consumer brand, Tru Niagen—creates strong operating leverage and margin expansion, with gross margins exceeding 60%. Years of FDA engagement, consumer education, and consistent manufacturing purity have built deep distribution trust and channel lock-in.

Upcoming catalysts include new B2B launches with global CPG partners, clinical data expanding therapeutic potential, and sustained regulatory recognition of NR’s safety profile. While category confusion and shifting supplement regulations pose near-term risks, Niagen’s regulatory legitimacy, profitability, and expanding adoption position it as the only longevity play combining patents, profits, and permission. NAGE offers a unique, cash-generative exposure to the growing cellular health and rejuvenation megatrend, supported by real science and recurring cash flows.

Previously we covered a bullish thesis on Herbalife Ltd. (HLF) by Prateek Malhotra in October 2024, which highlighted the company’s undervaluation, insider accumulation, and restructuring-led margin expansion. The company’s stock price has appreciated approximately by 143.96% since our coverage. This is because the thesis played out as operational stability improved. The thesis still stands as deleveraging supports future upside. Ridire Research shares a similar but emphasizes Niagen Bioscience’s regulatory moats and profitability within the wellness sector.

Niagen Bioscience, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held NAGE at the end of the second quarter which was 15 in the previous quarter. While we acknowledge the potential of NAGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.